← Back to Search

CAR T-cell Therapy

AMV564 for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by Amphivena Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during dose expansion, an average of 1 year
Awards & highlights

Summary

This trial is testing a new drug to see if it is safe and effective in treating patients with advanced solid tumors.

Eligible Conditions
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during dose expansion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and during dose expansion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Treatment-Related Adverse Events
Maximum tolerated dose of AMV564 in subjects with advanced solid tumors
Preliminary evaluation of AMV564 efficacy in subjects enrolled in the expansion phase
Secondary outcome measures
Apparent terminal half-life (t½) of AMV564
Area under the concentration-time curve (AUC) of AMV564
Concentration at steady state (Css) of AMV564
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: AMV564Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AMV564
2017
Completed Phase 1
~60

Find a Location

Who is running the clinical trial?

Amphivena Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
67 Total Patients Enrolled
Patrick Chun, MDStudy DirectorAmphivena Therapeutics
2 Previous Clinical Trials
67 Total Patients Enrolled
~11 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top